Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common stock
-
Shares outstanding
-
47.1M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
12.8M
-
Shares change
-
-2.24M
-
Total reported value, excl. options
-
$25.8M
-
Value change
-
-$10.7M
-
Put/Call ratio
-
0.51
-
Number of buys
-
31
-
Number of sells
-
-28
-
Price
-
$2.02
Significant Holders of Whitehawk Therapeutics, Inc. - Common stock (WHWK) as of Q4 2023
81 filings reported holding WHWK - Whitehawk Therapeutics, Inc. - Common stock as of Q4 2023.
Whitehawk Therapeutics, Inc. - Common stock (WHWK) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.8M shares
of 47.1M outstanding shares and own 27.09% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (2.85M shares), ACUTA CAPITAL PARTNERS, LLC (1.85M shares), Alerce Investment Management, L.P. (1.63M shares), BlackRock Inc. (1.08M shares), VANGUARD GROUP INC (860K shares), Decheng Capital LLC (526K shares), MORGAN STANLEY (511K shares), Vivo Capital, LLC (510K shares), CITADEL ADVISORS LLC (408K shares), and RENAISSANCE TECHNOLOGIES LLC (399K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.